Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

963 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Rühl U, Müller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Rüffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V. Dühmke E, et al. Among authors: kirchner h. J Clin Oncol. 2001 Jun 1;19(11):2905-14. doi: 10.1200/JCO.2001.19.11.2905. J Clin Oncol. 2001. PMID: 11387364 Clinical Trial.
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Pfreundschuh M, Hasenclever D, Loeffler M, Ehninger G, Schmitz N, Kirchner H, Koch P, Lathan B, Rueffer U, Sextro M, Franklin J, Tesch H, Diehl V; German Hodgkin's Lymphoma Study Group. Pfreundschuh M, et al. Among authors: kirchner h. Ann Oncol. 2001 Apr;12(4):471-7. doi: 10.1023/a:1011108722666. Ann Oncol. 2001. PMID: 11398878 Free article. Clinical Trial.
Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
Loeffler M, Diehl V, Pfreundschuh M, Rühl U, Hasenclever D, Nisters-Backes H, Sieber M, Tesch H, Franklin J, Geilen W, Bartels H, Cartoni C, Dölken G, Enzian J, Fuchs R, Gassmann W, Gerhartz H, Hagen-Aukamp U, Hiller E, Hinkelbein H, Hinterberger W, Kirchner H, Koch P, Krüger B, Schwarze EW, et al. Loeffler M, et al. Among authors: kirchner h. J Clin Oncol. 1997 Jun;15(6):2275-87. doi: 10.1200/JCO.1997.15.6.2275. J Clin Oncol. 1997. PMID: 9196141 Clinical Trial.
Cooperative trials of Hodgkin's lymphoma in the Federal Republic of Germany.
Diehl V, Pfreundschuh M, Löffler M, Rühl U, Hiller E, Gerhartz H, Kirchner H. Diehl V, et al. Among authors: kirchner h. J Cancer Res Clin Oncol. 1990;116(1):106-8. doi: 10.1007/BF01612650. J Cancer Res Clin Oncol. 1990. PMID: 1690208 Clinical Trial. No abstract available.
Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group.
Hiddemann W, Schmitz N, Pfreundschuh M, Pflüger KH, Ollech-Chwoyka J, Tirier C, Maschmeyer G, Kirchner H, Wagner T, Koch P, et al. Hiddemann W, et al. Among authors: kirchner h. Cancer. 1990 Sep 1;66(5):838-43. doi: 10.1002/1097-0142(19900901)66:5<838::aid-cncr2820660504>3.0.co;2-r. Cancer. 1990. PMID: 2386912
Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.
Diehl V, Pfreundschuh M, Löffler M, Rühl U, Hiller E, Gerhartz H, Wilmanns W, Kirchner H, Schoppe W, Petsch S, et al. Diehl V, et al. Among authors: kirchner h. Med Oncol Tumor Pharmacother. 1989;6(2):155-62. doi: 10.1007/BF02985239. Med Oncol Tumor Pharmacother. 1989. PMID: 2473363 Clinical Trial.
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M; Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Atzpodien J, et al. Among authors: kirchner h. J Clin Oncol. 2004 Apr 1;22(7):1188-94. doi: 10.1200/JCO.2004.06.155. Epub 2004 Feb 23. J Clin Oncol. 2004. PMID: 14981107 Clinical Trial.
963 results